Sean Ainsworth, Chief Executive Officer and Chairman of the Board  Oct. 11 | 2:15pm | Oxford Biomedica Ballroom    Seattle, WA  (Private)  In-person Presentation  Our mission at Immusoft is to develop novel cell therapies by programming B cells to produce therapeutic proteins that improve the lives of patients with...

Angela Columbano, Ph.D., Head Business Development and Partnership  Oct. 13 | 9:30am | Oxford Biomedica Ballroom  Evry, France  (Private)  In-person Presentation  Genethon has been pioneering gene therapy for 30 years. Genethon’s teams have originated multiple gene therapy successes that are now bringing tremendous benefits for patients. Dedicated to tackling rare diseases,...

Tim Miller, Ph.D., CEO, President, and Co-Founder, Forge Biologics  Oct. 12 | 9:15am | Oxford Biomedica Ballroom  Grove City, OH   (Private)  In-person Presentation  Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and...

Bill Symonds, Ph.D., CEO Oct. 12 | 5:30pm | UBC Ballroom   Cambridge, MA  (Private)  In-person Presentation  Enzyvant is a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases. The company’s first commercial product is FDA-approved RETHYMIC® (allogeneic processed thymus tissue-agdc), a tissue-based regenerative therapy for an ultra-rare and life-threatening...

Emile Nuwaysir, Ph.D., President and CEO  Oct. 11 | 12:00pm | Oxford Biomedica Ballroom  Boston, MA  (Private)  In-person Presentation  Ensoma is a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within. The company is poised to create a...

Ryan Pruchnic, Managing Vice President   Oct. 13 | 9:00am | Oxford Biomedica Ballroom   Pittsburgh, PA  (Private)  In-person Presentation  In 2002 Cook MyoSite was formed to guide the Cook Group organization into the expanding world of cellular technologies. Today, Cook MyoSite is dedicated to the development and subsequent commercialization of technology related...

Seth Ettenberg, Ph.D., CEO  Oct. 11 | 10:00am | Oxford Biomedica Ballroom  Cambridge, MA  (Private)  In-person Presentation  BlueRock Therapeutics is a leading engineered cell therapy company with a mission to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition. The company’s cell+gene platform harnesses...

RW Mays, Ph.D., Vice President of Regenerative Medicine  Oct. 11 | 4:00pm | Oxford Biomedica Ballroom  Cleveland, OH  (NASDAQ: ATHX)  In-person Presentation  Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of...

Devyn Smith, Ph.D., CEO Oct. 11 | 2:30pm | Oxford Biomedica Ballroom  Cambridge, MA  (Private)  In-person Presentation  Arbor Biotechnologies is a life sciences company discovering and developing the next generation of genetic medicines based on wholly owned genomic editors discovered from its machine learning/AI driven discovery platform. Since its founding in...

Jim Williams, Ph.D., Vice President R&D and Chief Scientific Officer, Nature Technology, an Aldevron company Oct. 12 | 9:45am | Oxford Biomedica Ballroom  Fargo, ND  (NASDAQ: DHR)  In-person Presentation  Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA, and...

By using this website you agree to accept our Privacy Policy and Terms & Conditions